Moderna (MRNA) Short-term Investments (2017 - 2026)

Moderna (MRNA) has 10 years of Short-term Investments data on file, last reported at $3.3 billion in Q1 2026.

• On a quarterly basis, Short-term Investments fell 24.24% year-over-year to $3.3 billion in Q1 2026; TTM through Mar 2026 was $3.3 billion, a 24.24% decrease from a year earlier, with the FY2025 full-year figure at $3.2 billion, down 37.15% from the prior year.
• Short-term Investments for Q1 2026 stood at $3.3 billion, up from $3.2 billion in the prior quarter.
• Over the last five years, Short-term Investments for MRNA reached as high as $6.7 billion in Q4 2022 and fell as low as $3.2 billion in Q4 2025.
• Historically, Short-term Investments has averaged $4.9 billion across 5 years, with a median of $5.1 billion in 2022.
• Across the five-year window, Short-term Investments soared 120.98% in 2022 and sank 37.15% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $6.7 billion in 2022, then decreased by 14.93% to $5.7 billion in 2023, then retreated by 10.51% to $5.1 billion in 2024, then sank by 37.15% to $3.2 billion in 2025, then increased by 2.9% to $3.3 billion in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $3.3 billion in Q1 2026, $3.2 billion in Q4 2025, and $3.4 billion in Q3 2025.